532 related articles for article (PubMed ID: 16548099)
1. Celecoxib: new indication. Colorectal cancer: no preventive benefit.
Prescrire Int; 2006 Feb; 15(81):13-5. PubMed ID: 16548099
[TBL] [Abstract][Full Text] [Related]
2. [Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis].
Sheng JQ; Li SR; Yang XY; Zhang YH; Su H; Yu DL; Yan W; Geng HG
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(8):526-9. PubMed ID: 16681880
[TBL] [Abstract][Full Text] [Related]
3. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
Steinbach G; Lynch PM; Phillips RK; Wallace MH; Hawk E; Gordon GB; Wakabayashi N; Saunders B; Shen Y; Fujimura T; Su LK; Levin B; Godio L; Patterson S; Rodriguez-Bigas MA; Jester SL; King KL; Schumacher M; Abbruzzese J; DuBois RN; Hittelman WN; Zimmerman S; Sherman JW; Kelloff G
N Engl J Med; 2000 Jun; 342(26):1946-52. PubMed ID: 10874062
[TBL] [Abstract][Full Text] [Related]
4. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
[TBL] [Abstract][Full Text] [Related]
5. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
[TBL] [Abstract][Full Text] [Related]
6. Use of NSAIDs for the chemoprevention of colorectal cancer.
Herendeen JM; Lindley C
Ann Pharmacother; 2003 Nov; 37(11):1664-74. PubMed ID: 14565811
[TBL] [Abstract][Full Text] [Related]
7. Celecoxib for the prevention of colorectal adenomatous polyps.
Arber N; Eagle CJ; Spicak J; Rácz I; Dite P; Hajer J; Zavoral M; Lechuga MJ; Gerletti P; Tang J; Rosenstein RB; Macdonald K; Bhadra P; Fowler R; Wittes J; Zauber AG; Solomon SD; Levin B;
N Engl J Med; 2006 Aug; 355(9):885-95. PubMed ID: 16943401
[TBL] [Abstract][Full Text] [Related]
8. The safety and efficacy of celecoxib in children with familial adenomatous polyposis.
Lynch PM; Ayers GD; Hawk E; Richmond E; Eagle C; Woloj M; Church J; Hasson H; Patterson S; Half E; Burke CA
Am J Gastroenterol; 2010 Jun; 105(6):1437-43. PubMed ID: 20234350
[TBL] [Abstract][Full Text] [Related]
9. [Role of suindac in the treatment of familial adenomatous polyposis coli].
Landauer S; Halimi C; Caulin C; Bergmann JF
Therapie; 1999; 54(6):675-82. PubMed ID: 10709439
[TBL] [Abstract][Full Text] [Related]
10. Prevention of gastrointestinal cancer--the potential role of NSAIDs in colorectal cancer.
Luk GD
Schweiz Med Wochenschr; 1996 May; 126(19):801-12. PubMed ID: 8693304
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
Solomon SD; McMurray JJ; Pfeffer MA; Wittes J; Fowler R; Finn P; Anderson WF; Zauber A; Hawk E; Bertagnolli M;
N Engl J Med; 2005 Mar; 352(11):1071-80. PubMed ID: 15713944
[TBL] [Abstract][Full Text] [Related]
12. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.
White WB; West CR; Borer JS; Gorelick PB; Lavange L; Pan SX; Weiner E; Verburg KM
Am J Cardiol; 2007 Jan; 99(1):91-8. PubMed ID: 17196469
[TBL] [Abstract][Full Text] [Related]
13. The adenoma prevention with celecoxib and prevention of colorectal sporadic adenomatous polyps trials: stepping stones to progress.
Hawk E; Viner JL
Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):185-7. PubMed ID: 17301246
[No Abstract] [Full Text] [Related]
14. Aspirin and other nonsteroidal anti-inflammatory agents in the prevention of colorectal cancer.
Sandler RS
Important Adv Oncol; 1996; ():123-37. PubMed ID: 8791132
[TBL] [Abstract][Full Text] [Related]
15. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.
Solomon SD; Pfeffer MA; McMurray JJ; Fowler R; Finn P; Levin B; Eagle C; Hawk E; Lechuga M; Zauber AG; Bertagnolli MM; Arber N; Wittes J;
Circulation; 2006 Sep; 114(10):1028-35. PubMed ID: 16943394
[TBL] [Abstract][Full Text] [Related]
16. Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?
Gill S; Sinicrope FA
Semin Oncol; 2005 Feb; 32(1):24-34. PubMed ID: 15726503
[TBL] [Abstract][Full Text] [Related]
17. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
Singh G; Fort JG; Goldstein JL; Levy RA; Hanrahan PS; Bello AE; Andrade-Ortega L; Wallemark C; Agrawal NM; Eisen GM; Stenson WF; Triadafilopoulos G;
Am J Med; 2006 Mar; 119(3):255-66. PubMed ID: 16490472
[TBL] [Abstract][Full Text] [Related]
18. Celecoxib as adjunctive therapy for treatment of colorectal cancer.
North GL
Ann Pharmacother; 2001 Dec; 35(12):1638-43. PubMed ID: 11793634
[TBL] [Abstract][Full Text] [Related]
19. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
Goldstein JL; Cryer B; Amer F; Hunt B
Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1167-74. PubMed ID: 17916545
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study.
Sieper J; Klopsch T; Richter M; Kapelle A; Rudwaleit M; Schwank S; Regourd E; May M
Ann Rheum Dis; 2008 Mar; 67(3):323-9. PubMed ID: 17616556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
